|
EB-G3B7-NK dual-target CAR-NK cells Clinical Trials
1 actively recruiting trial
No change since May 2026
Also known as: Dual-target GPC3/B7-H3 CAR-NK; G3B7-NK; EB-G3B7-NK
Pipeline
Phase 1/2: 1
Top Sponsors
- Beijing Biotech1
Indications
- Liver Disease1
- Advanced Hepatocellular Carcinoma (HCC)1
- Metastatic Liver Cancer1
- Liver Cancer1
- Cancer1
Other1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.